Table 4.
Immunosuppressive therapies in all AAV patients including survivors and nonsurvivors.
| Parameters | All
(n = 34) |
Survivors
(n = 14) |
Nonsurvivors
(n = 20) |
P value | |
|---|---|---|---|---|---|
| Before ICU admission | Methylprednisolone, n (%) | 26 (76.5) | 9 (64.3) | 17 (85) | 0.167 |
| Cyclophosphamide, n (%) | 20 (58.8) | 7 [50] | 13 (65) | 0.389 | |
| Rituximab, n (%) | 6 (17.6) | 3 (21.4) | 3 (15) | 0.634 | |
| Plasmapheresis, n (%) | 16 (47.1) | 4 (28.6) | 12 (60) | 0.075 | |
| Total seans*, count | 5 [4–7] | 5 [2–9] | 6 [4–7] | 0.691 | |
| During ICU stay | Methylprednisolone, n (%) | 31 (91.2) | 13 (92.9) | 18 (90) | 0.776 |
| Cyclophosphamide, n (%) | 7 (20.6) | 5 (35.7) | 2 (10) | 0.072 | |
| Rituximab, n (%) | 1 (2.9) | - | 1 (5) | - | |
| Plasmapheresis, n (%) | 18 (52.9) | 8 (57.1) | 10 (50) | 0.686 | |
| Total seans*, count | 4 [3–5] | 5 [3–6] | 3 [3–5] | 0.256 |
*Data are presented as median [interquartile range] AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; n: number; ICU: Intensive Care Unit